Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug;2(4):200-208.
doi: 10.4021/gr2009.07.1305. Epub 2009 Jul 20.

Common Pitfalls in Management of Inflammatory Bowel Disease

Lakshmi Pasumarthy  1 , James Srour  1 , Cuckoo Choudhary  2
Affiliations
Review

Common Pitfalls in Management of Inflammatory Bowel Disease

Lakshmi Pasumarthy et al. Gastroenterology Res. 2009 Aug.

Abstract

Our understanding of inflammatory bowel disease (IBD), treatment options, complications and their management has expanded significantly over the past few decades. When caring for patients it is important to remember the complexities of pathogenesis and pharmacology. This review is to identify errors in diagnosis, treatment, complications and preventive care issues that arise while caring for patients with IBD and to provide recommendations and information that can be shared with patients and their health care providers. A review of the literature was undertaken using MEDLINE from 1981 to present. We included randomized controlled studies, case-control studies, and review articles. There are many associated conditions and complications recognized in patients with IBD and current treatment strategies do result in many side effects, some are serious and some are not widely recognized. With the advent of anti-TNF therapies and the newer 5-amino salicylate derivatives, options available have increased significantly. It is also important to remember that these patients are followed by more than one health care provider and it is important for all involved to communicate the plan of action.

Keywords: 6-mercaptopurine; Azathioprine; Crohn’s disease; Inflammatory bowel disease; Tumor necrosis factor; Ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The suggested management of dyplasia in IBD
See this image and copyright information in PMC

References

    1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517. doi: 10.1053/j.gastro.2004.01.063. - DOI - PubMed
    1. Austin GL, Shaheen NJ, Sandler RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am J Gastroenterol. 2006;101(3):413–416. doi: 10.1111/j.1572-0241.2006.00475.x. - DOI - PubMed
    1. Austin GL, Herfarth HH, Sandler RS. A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(5):545–547. doi: 10.1016/j.cgh.2007.03.006. - DOI - PubMed
    1. Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc. 1995;42(3):232–237. doi: 10.1016/S0016-5107(95)70097-8. - DOI - PubMed
    1. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T. et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut. 1997;40(3):328–332. - PMC - PubMed

LinkOut - more resources